Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial
Background: Hand Foot Syndrome (HFS) is a frequent adverse effect observed in patients undergoing capecitabine chemotherapy, often leading to treatment disruptions and dose adjustments. Elevated C-Reactive Protein (hs-CRP) levels have been associated with the development of HFS. This study aimed to...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2024-01-01
|
| Series: | Acta Medica Indonesiana |
| Subjects: | |
| Online Access: | http://www.actamedindones.org/index.php/ijim/article/view/2534 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849432535160848384 |
|---|---|
| author | Yenny Dian Andayani Mgs. Irsan Saleh Aru Wisaksono Sudoyo Zulkhair Ali Legiran Legiran Radiyati Umi Partan Eddy Yuristo Fadhyl Zuhry Lubis |
| author_facet | Yenny Dian Andayani Mgs. Irsan Saleh Aru Wisaksono Sudoyo Zulkhair Ali Legiran Legiran Radiyati Umi Partan Eddy Yuristo Fadhyl Zuhry Lubis |
| author_sort | Yenny Dian Andayani |
| collection | DOAJ |
| description |
Background: Hand Foot Syndrome (HFS) is a frequent adverse effect observed in patients undergoing capecitabine chemotherapy, often leading to treatment disruptions and dose adjustments. Elevated C-Reactive Protein (hs-CRP) levels have been associated with the development of HFS. This study aimed to assess the potential of unrefined Extra Virgin Olive Oil (EVOO) supplementation in mitigating HFS and hs-CRP elevation among individuals receiving capecitabine chemotherapy. Methods: Between November 2022 and May 2023, forty-five eligible participants were enrolled in this randomized trial. Patients with advanced colorectal or breast cancer were randomly allocated into three groups: an intervention group receiving unrefined EVOO supplementation (30 mL per day) alongside capecitabine, a placebo group receiving refined extra light olive oil (ELOO) supplementation (30 mL per day) alongside capecitabine, and a control group receiving capecitabine alone. The masking of both placebo and intervention groups was ensured through identical packaging and instructions, maintaining participant and physician blindness to the assigned treatments. Randomization, achieved via computer-generated sequences, ensured even distribution among the three groups. Results: HFS incidences were notably lower in the EVOO group (13.3%) compared to the placebo (66.7%) and control (80%) groups. Instances of Grade 2 or more severe HFS were observed in 20% of placebo and 40% of control group patients. No cases of severe HFS were reported in the EVOO group. Moreover, EVOO supplementation led to a significant reduction in hs-CRP levels when contrasted with the placebo and control groups. These findings suggest that EVOO may serve as a preventive measure against HFS and exhibit anti-inflammatory effects in patients undergoing capecitabine chemotherapy. Conclusion: This study demonstrates the potential benefits of incorporating unrefined EVOO into the regimen of patients undergoing capecitabine chemotherapy. EVOO supplementation was associated with lower incidences of HFS and a reduction in hs-CRP levels, indicating its possible role in preventing HFS development and mitigating inflammation.
|
| format | Article |
| id | doaj-art-bb83896d8a4d40b3aa3d535080729104 |
| institution | Kabale University |
| issn | 0125-9326 2338-2732 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | Acta Medica Indonesiana |
| spelling | doaj-art-bb83896d8a4d40b3aa3d5350807291042025-08-20T03:27:21ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322024-01-01554Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized TrialYenny Dian Andayani0Mgs. Irsan Saleh1Aru Wisaksono Sudoyo2Zulkhair Ali3Legiran Legiran4Radiyati Umi Partan5Eddy Yuristo6Fadhyl Zuhry Lubis7Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Sriwijaya - Mohammad Hoesin General Hospital, Palembang, IndonesiaDepartment of Pharmacology, Faculty of Medicine, Universitas Sriwijaya, Palembang, IndonesiaDivision of Haematology and Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, IndonesiaDivision of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine Universitas Sriwijaya - Mohammad Hoesin General Hospital, Palembang, IndonesiaDepartment of Anatomy, Faculty of Medicine, Universitas Sriwijaya, Palembang, IndonesiaDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine Universitas Sriwijaya - Mohammad Hoesin Hospital, Palembang, IndonesiaDepartment of Internal Medicine, Faculty of Medicine Universitas Sriwijaya - Mohammad Hoesin General Hospital, Palembang, IndonesiaDepartment of Internal Medicine, Faculty of Medicine Universitas Sriwijaya - Mohammad Hoesin General Hospital, Palembang, Indonesia Background: Hand Foot Syndrome (HFS) is a frequent adverse effect observed in patients undergoing capecitabine chemotherapy, often leading to treatment disruptions and dose adjustments. Elevated C-Reactive Protein (hs-CRP) levels have been associated with the development of HFS. This study aimed to assess the potential of unrefined Extra Virgin Olive Oil (EVOO) supplementation in mitigating HFS and hs-CRP elevation among individuals receiving capecitabine chemotherapy. Methods: Between November 2022 and May 2023, forty-five eligible participants were enrolled in this randomized trial. Patients with advanced colorectal or breast cancer were randomly allocated into three groups: an intervention group receiving unrefined EVOO supplementation (30 mL per day) alongside capecitabine, a placebo group receiving refined extra light olive oil (ELOO) supplementation (30 mL per day) alongside capecitabine, and a control group receiving capecitabine alone. The masking of both placebo and intervention groups was ensured through identical packaging and instructions, maintaining participant and physician blindness to the assigned treatments. Randomization, achieved via computer-generated sequences, ensured even distribution among the three groups. Results: HFS incidences were notably lower in the EVOO group (13.3%) compared to the placebo (66.7%) and control (80%) groups. Instances of Grade 2 or more severe HFS were observed in 20% of placebo and 40% of control group patients. No cases of severe HFS were reported in the EVOO group. Moreover, EVOO supplementation led to a significant reduction in hs-CRP levels when contrasted with the placebo and control groups. These findings suggest that EVOO may serve as a preventive measure against HFS and exhibit anti-inflammatory effects in patients undergoing capecitabine chemotherapy. Conclusion: This study demonstrates the potential benefits of incorporating unrefined EVOO into the regimen of patients undergoing capecitabine chemotherapy. EVOO supplementation was associated with lower incidences of HFS and a reduction in hs-CRP levels, indicating its possible role in preventing HFS development and mitigating inflammation. http://www.actamedindones.org/index.php/ijim/article/view/2534Hand Foot SyndromeC-Reactive ProteinExtra Virgin Olive OilCapecitabine |
| spellingShingle | Yenny Dian Andayani Mgs. Irsan Saleh Aru Wisaksono Sudoyo Zulkhair Ali Legiran Legiran Radiyati Umi Partan Eddy Yuristo Fadhyl Zuhry Lubis Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial Acta Medica Indonesiana Hand Foot Syndrome C-Reactive Protein Extra Virgin Olive Oil Capecitabine |
| title | Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial |
| title_full | Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial |
| title_fullStr | Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial |
| title_full_unstemmed | Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial |
| title_short | Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial |
| title_sort | effect of extra virgin olive oil on hand foot syndrome and hs crp in patients receiving capecitabine a randomized trial |
| topic | Hand Foot Syndrome C-Reactive Protein Extra Virgin Olive Oil Capecitabine |
| url | http://www.actamedindones.org/index.php/ijim/article/view/2534 |
| work_keys_str_mv | AT yennydianandayani effectofextravirginoliveoilonhandfootsyndromeandhscrpinpatientsreceivingcapecitabinearandomizedtrial AT mgsirsansaleh effectofextravirginoliveoilonhandfootsyndromeandhscrpinpatientsreceivingcapecitabinearandomizedtrial AT aruwisaksonosudoyo effectofextravirginoliveoilonhandfootsyndromeandhscrpinpatientsreceivingcapecitabinearandomizedtrial AT zulkhairali effectofextravirginoliveoilonhandfootsyndromeandhscrpinpatientsreceivingcapecitabinearandomizedtrial AT legiranlegiran effectofextravirginoliveoilonhandfootsyndromeandhscrpinpatientsreceivingcapecitabinearandomizedtrial AT radiyatiumipartan effectofextravirginoliveoilonhandfootsyndromeandhscrpinpatientsreceivingcapecitabinearandomizedtrial AT eddyyuristo effectofextravirginoliveoilonhandfootsyndromeandhscrpinpatientsreceivingcapecitabinearandomizedtrial AT fadhylzuhrylubis effectofextravirginoliveoilonhandfootsyndromeandhscrpinpatientsreceivingcapecitabinearandomizedtrial |